Inclusion Criteria:  Individuals who meet all of the following criteria are eligible for enrollment as study participants:  Adult (age ≥18 years currently)  First-time renal transplant recipients of either living donor or deceased donors:  Treatment with belatacept from the time of transplant At least 2 years post-transplant and off CNI therapy for at least 6 months  Patients at low immunologic risk  First time transplant HLA antibody screen with PRA< 50%against class I and class II antigens Negative crossmatch (actual or virtual) No donor specific anti-HLA antibody (DSA) No more than one episode of rejection (Banff grade 1A or greater) No episodes of rejection (borderline or greater) within the last 6 months prior to study participation No rejection of Banff grade IIB or greater Immunosuppression consisting of belatacept (5mg/kg q 1M), mycophenolate mofetil (at least 1000 mg daily), or equivalent mycophenolic acid (720 mg daily) or azathioprine (1-2 mg/kg daily) dose, and prednisone 5 mg daily.  Exclusion Criteria:  Individuals who meet any of these criteria are not eligible for enrollment as study participants:  Repeat renal transplant, or multi-organ transplant recipient History of more than one episode of biopsy-proven acute rejection (Banff grade 1A or greater), or of any episode of rejection of Banff 97 grade IIB or greater, or any rejection (borderline or greater) within the last 6 months Pregnancy (women of childbearing potential must use adequate contraception during study) GFR less than 35 Serum creatinine at enrollment more than30% higher than at 3 months (±4 weeks) prior to randomization HbA1C greater than 8%within 3 months of enrollment (diabetic patients only) Recent history of clinically significant proteinuria (urinary protein/Cr ratio >1.0) Receiving belatacept at a dose other than 5 mg/kg body weight Receiving mycophenolate mofetil at a dose of less than 1000 mg po QD (or mycophenolic acid or azathioprine equivalent). - Receiving prednisone at a dose greater than 5 mg po qd within 3 months of enrollment Not currently receiving maintenance immunosuppression with prednisone Active infection, or antibiotic or antiviral drug therapy within 1 month of randomization Evidence of CMV viremia or clinical CMV infection within the last 3 months prior to randomization. BK viremia of greater then 4.3 DNA log copies/mL (greater than 20,000 copies/mL) within 3 months of randomization Known hepatitis B surface antigen-positive or PCR-positive for hepatitis B (testing not required) Known HIV-positivity(testing not required) Presence of donor specific antibody by Luminex single antigen bead assay, or antibody screen (% PRA) above 50%. History of substance abuse or psychiatric disorder not compatible with study adherence and follow up. History of medical noncompliance